Manufacturer record
SNG Pharmaceuticals (p) Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by SNG Pharmaceuticals (p) Ltd (Gujarat) were declared Not of Standard Quality between September 2025 and April 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
4 records linked to SNG Pharmaceuticals (p) Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Buprenorphine Injection IP | ASG1590Mfg 2022-11 · Exp 2026-10 | The sample does not conform to I.P. with respect to tests of Sterility and Assay of Buprenorphine.Assay | CDL, KolkataCDSCO lab | Apr 2026 |
| Buprenorphine Injection IP 2ml | 1364 ASOMfg 2025-06 · Exp 2028-05 | The sample does not conform to IP with respect to test for Sterility, Related Substances, Particulate matter, Assay of Buprenorphine Hydrochloride and Description.Assay | CDL, KolkataCDSCO lab | Jan 2026 |
| Buprenorphine Injection IP 2ml | 1364 ASOMfg 2024-05 · Exp 2026-04 | The sample does not conform to IP with respect to test for pH, Related Substance, Particulate matter and Assay of Buprenorphine Hydrochloride.Assay | CDL, KolkataCDSCO lab | Jan 2026 |
| LUPIGESIC Buprenorphine Injection IP 2ml | ASG 1590Mfg 2022-11 · Exp 2026-10 | sample does not conform to I.P. with respect to test for "Sterility", "Related substances", "Particulate matter", "Assay/content of Buprenorphine and "Description".Assay | CDL, KolkataCDSCO lab | Sep 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.